(PM) Berlin, 02.03.2012 - Nowadays the CIS and CEE Pharma markets develop very well, mostly above 15-17%. However the markets are still dominated by more than 80% imported products from West-Europe, Asia and the US. Will this change? What will change? We at Chameleon Pharma Consulting notice that more and more Russian, Ukrainian, Polish and Kazak investors and Pharma cooperations are interested to acquire healthcare or pharmaceutical products and companies in Western Europe.

Some players like the Slovenian KRKA Group have already made a move towards “west” some years ago. They bought the German Pharma company TAD in the North of the country. Others Russian investors are currently on
“a Pharma & Medical company target shopping tour” in Europe.

However Russian investors seam to be “slow movers” to invest into Medical or Pharma companies in Europe. This may happen due to the lack of market knowledge or other reasons. “Howerver such investments in Europe could definitely bring innovative products and techniques to the Russian healthcare market and investors could benefit from long term stable profits”, say Reiner Christensen, the CEO of Chameleon Pharma Consulting.

“We, Chameleon Pharma Consulting, had many interesting discussions with Russian investors during last months, but Russian players need to be quicker in the due diligence execution”, says Andreas Masel, the Pharma veteran of Chameleon Pharma Consulting. US and Asian investors seem to be faster so far to decide on innovative healthcare investments in Europe and thus earn the advantages from these smart steps.

Andreas Masel adds, “I would recommend Russian investors, interested in Pharma and Medical assets, balancing their portfolio and acquiring more targets in West-Europe. This could also bring good technologies to the CIS & CEE markets.”